4th Quarter - Report

ARENTFOX SCHIFF LLP for TRANSPARENCY-RX CORP.

Firm
Client
Income
$20,000
Expenses
—

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Pharmacy Benefit Manager Reform Transparency in prescription drug markets Prescription drug prices S. 891 (Bipartisan Health Care Act), regarding Pharmacy Benefit Manager reform, transparency in prescription drug markets, and prescription drug prices H.R. 4317 (PBM Reform Act of 2025), regarding Pharmacy Benefit Manager reform, transparency in prescription drug markets, and prescription drug prices

LobbyistCovered position, as disclosed
PHILIP ENGLISH —
KELSEY GRISWOLD-BERGER New Sr Policy Advisor, Sen McCormick (2025); LA, Sen Burr (2021-23); Leg Dir, Rep C Smith (2018-21); Leg Dir, Rep Pittenger (2018); Leg Dir, Rep Blum (2017-18); LA, Rep Perry (2015-17); LA (2014-15), LC/Press Asst (2011-14), SA (2011), Rep Reed
KATHERINE KRAMER —
DANIEL SJOSTEDT —
BLAKE THELANDER —

Contacted: Health & Human Services, Dept of (HHS); Labor, Dept of (DOL); SENATE; HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB)

Bills named: S. 891 (119th), H.R. 4317 (119th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.